| __timestamp | Genmab A/S | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 40786000 |
| Thursday, January 1, 2015 | 91224000 | 47876000 |
| Friday, January 1, 2016 | 102413000 | 52035000 |
| Sunday, January 1, 2017 | 146987000 | 55348000 |
| Monday, January 1, 2018 | 213695000 | 65276000 |
| Tuesday, January 1, 2019 | 342000000 | 82720000 |
| Wednesday, January 1, 2020 | 661000000 | 89118000 |
| Friday, January 1, 2021 | 1283000000 | 181193000 |
| Saturday, January 1, 2022 | 2676000000 | 174078000 |
| Sunday, January 1, 2023 | 3297000000 | 184232000 |
| Monday, January 1, 2024 | 3790000000 |
Cracking the code
In the ever-evolving landscape of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Veracyte, Inc. from 2014 to 2023. Genmab A/S, a leader in antibody therapeutics, has seen its SG&A expenses skyrocket by over 4,000% during this period, reflecting its aggressive expansion and investment in innovation. In contrast, Veracyte, Inc., a pioneer in genomic diagnostics, has maintained a more modest growth in SG&A expenses, increasing by approximately 350%. This stark difference highlights Genmab's rapid scaling strategy compared to Veracyte's steady growth approach. As the biotech sector continues to grow, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.
Selling, General, and Administrative Costs: AbbVie Inc. vs Veracyte, Inc.
Merck & Co., Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Veracyte, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?